Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a lab test tell which chemo works for colon cancer?

NCT ID NCT07830407

NEW Diagnosis Sponsor: Pierian Biosciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are studying whether a laboratory test called ChemoINTEL can predict how a patient's colorectal cancer will respond to chemotherapy. The study enrolls 100 adults with colorectal cancer, including those receiving adjuvant chemotherapy, those with high-risk stage II disease not receiving chemotherapy, and those with locally advanced rectal cancer who responded completely to chemoradiotherapy. Tumor samples and optional blood samples go to a lab, where scientists run the assay without seeing clinical details. The goal is to see if the test's predictions match how patients actually respond, measured by ctDNA in the blood after chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ChemoINTEL assay, a lab test that measures chemotherapy-induced cell death in a patient's tumor cells
What this could lead to
If the assay predicts chemotherapy response accurately, doctors could one day choose colorectal cancer drugs based on a patient's tumor biology rather than trial and error.
What could go wrong
This is an early observational study with 100 participants, and the assay results are not shared with treating doctors. The test may not predict real-world outcomes, and it is not yet a proven clinical tool.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Colorectal Cancer Diagnosis

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Group 1 Participants: 1. ≥18 years of age 2. Diagnosis of CRC i. Surgical resection followed by adjuvant chemotherapy ii. Biopsy followed by neoadjuvant chemo/radiotherapy and surgical resection. 3. Patients planned to receive at least 6 cycles of standard of care chemotherapy for CRC with single agent or combination of drugs listed in Table 3 following biopsy OR surgical resection 4. One solid tumor specimen is required; a total of two specimens are preferred and requested when available. Specimens will include: i. Primary solid tumor specimen (≥400 mg) ii. Adjacent normal tissue (\>400mg) 5. Patient signed Informed Consent Form Exclusion Criteria Group 1 Participants: 1. Patient has not signed an ICF to participate in a clinical investigation 2. Patient has a cancer other than advanced stage CRC 3. Patient is NOT expected to receive SOC chemotherapy, single agents or combination treatment, as listed in Table 3 4. Patients who do not have at sufficient viable cells recovered from fresh tumor dissociation available for the ChemoINTEL assay analysis of Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Capecitabine

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Liverpool University Hospital NHS Foundation Trust

    RECRUITING

    Liverpool, Merseyside, L7 8YE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.